Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Velicept Therapeutics

Request full access

Privately held clinical development

Malvern, United StatesFounded 2015Biotech & Life Sciences

About Velicept Therapeutics

Velicept Therapeutics, Inc. was a clinical-stage pharmaceutical company focused on developing treatments for urological and gastrointestinal disorders. The company was formed in 2015 through a merger between NeXeption and AltheRx Pharmaceuticals to advance the development of its lead candidate, solabegron. The company was led by President and CEO, Dr. James Walker, an executive with prior experience at Schering-Plough and as the founder and CEO of Octagon Research Solutions, which was acquired by Accenture. Unfortunately, after raising significant capital and advancing its lead product through mid-stage clinical trials, the company appears to have ceased operations around July 2022.

Velicept's primary asset was solabegron, a highly selective beta-3 adrenoceptor agonist. This compound works by relaxing the bladder's smooth muscle, representing a different mechanism compared to many existing treatments. The company's business model was centered on the clinical development and eventual commercialization of solabegron. Its target market included patients suffering from overactive bladder (OAB) and irritable bowel syndrome (IBS), conditions affecting a large and growing segment of the population. Revenue would have been generated from the sale of the approved drug. The development of solabegron was originally initiated by GlaxoSmithKline before being acquired by AltheRx in 2011, and then subsequently by Velicept through the 2015 merger.

The company's strategy involved progressing solabegron through a series of clinical trials to establish its safety and efficacy. Completed Phase 2 studies for OAB showed that solabegron provided a statistically significant improvement in symptoms compared to a placebo, including a reduction in incontinence episodes and daily voids. An important feature noted in these studies was a tolerability profile similar to placebo, with patients not experiencing common side effects like dry mouth or changes in blood pressure. Velicept also developed a novel once-daily formulation to improve convenience and initiated Phase 2b studies to evaluate different dosages. In 2019, the company announced positive top-line results from one of its Phase 2b studies, which met its primary endpoint. Despite these promising clinical milestones and raising over $42 million in funding from investors like Samsara BioCapital, Longitude Capital, and Fountain Healthcare Partners, Velicept was ultimately put up for sale through an Assignment for the Benefit of Creditors in late 2020 and is now listed as out of business.

Source: Dealroom company data

At a glance

Status
Operational
Open positions
None listed
Dealroom signal
50.6/100
Industry
Health
Sub-industry
Pharmaceutical
Sector
Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
Client focus
B2B
Links
Website

Funding history

4 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
DEBTDebt Nov 2019 $6M — Undisclosed —
SERIES B✓Equity / VC Oct 2018 $15M $60M Fountain Healthcare Partners · Longitude Capital · Samsara BioCapital —
Showing the latest 2 of 4 recorded eventsBook a demo for the full funding history →

Growth signals

Velicept Therapeutics website traffic

Latest recorded traffic for Velicept Therapeutics is 480 monthly website visits, up 92% over the last three months.

Latest monthly visits480 3-month web change+92%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Velicept Therapeutics in the Malvern ecosystem

Live from Dealroom

The Velicept Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

3 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A3 investors entered at this stage

  • Longitude Capital
  • Samsara BioCapital
  • Fountain Healthcare Partners
Team profiled 4 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 1 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
🇺🇸 United States · Malvern HQ
Book a demo for the full country breakdown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Velicept Therapeutics on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Velicept Therapeutics’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.